Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some ...

Mohammed Milhem, MBBS discussed the mechanism of action of RP1, the design and preliminary findings of the IGNYTE trial in ...

INX-315 is an oral, investigational selective cyclin-dependent kinase 2 (CDK2) inhibitor. The designation was based on preclinical data as well as interim data from the ongoing phase 1/2 INX-315-01 ...

Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial in the United States for its NTS071, a novel small molecule allosteric reactivator targeting ...

A new study published in the Metabolites journal found that SGLT2 inhibitors (SGLT2i) significantly reduced total cholesterol ...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented 6 study results of innovative drugs and platforms in poster format at the American Association ...

Q1 2025 Management View CEO Pascal Soriot emphasized that AstraZeneca's total revenue grew by 10% in Q1 2025, with core operating profit increasing by 12% and core EPS by 21%. Growth was supported by ...